KR102753603B1 - 신규한 Nav1.7 모노클로날 항체 - Google Patents

신규한 Nav1.7 모노클로날 항체 Download PDF

Info

Publication number
KR102753603B1
KR102753603B1 KR1020247018286A KR20247018286A KR102753603B1 KR 102753603 B1 KR102753603 B1 KR 102753603B1 KR 1020247018286 A KR1020247018286 A KR 1020247018286A KR 20247018286 A KR20247018286 A KR 20247018286A KR 102753603 B1 KR102753603 B1 KR 102753603B1
Authority
KR
South Korea
Prior art keywords
amino acid
acid sequence
seq
variable region
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020247018286A
Other languages
English (en)
Korean (ko)
Other versions
KR20240099394A (ko
Inventor
마이 요시카와
준지 오노다
다이키 나카모리
다츠야 다카하시
에리카 가사이
Original Assignee
시오노기세이야쿠가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시오노기세이야쿠가부시키가이샤 filed Critical 시오노기세이야쿠가부시키가이샤
Publication of KR20240099394A publication Critical patent/KR20240099394A/ko
Application granted granted Critical
Publication of KR102753603B1 publication Critical patent/KR102753603B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020247018286A 2021-11-01 2022-10-31 신규한 Nav1.7 모노클로날 항체 Active KR102753603B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JPJP-P-2021-178982 2021-11-01
JP2021178982 2021-11-01
JP2022005967 2022-01-18
JPJP-P-2022-005967 2022-01-18
PCT/JP2022/040580 WO2023074888A1 (ja) 2021-11-01 2022-10-31 新規なＮａｖ１．７モノクローナル抗体

Publications (2)

Publication Number Publication Date
KR20240099394A KR20240099394A (ko) 2024-06-28
KR102753603B1 true KR102753603B1 (ko) 2025-01-13

Family

ID=86159498

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247018286A Active KR102753603B1 (ko) 2021-11-01 2022-10-31 신규한 Nav1.7 모노클로날 항체

Country Status (12)

Country Link
US (1) US20250163145A1 (https=)
EP (1) EP4428239A4 (https=)
JP (1) JP7457880B2 (https=)
KR (1) KR102753603B1 (https=)
AU (1) AU2022377536B2 (https=)
CA (1) CA3236404A1 (https=)
CO (1) CO2024003915A2 (https=)
IL (1) IL311683B2 (https=)
MX (1) MX2024004393A (https=)
MY (1) MY206945A (https=)
TW (1) TWI867354B (https=)
WO (1) WO2023074888A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024225446A1 (ja) * 2023-04-28 2024-10-31 塩野義製薬株式会社 新規なＮａｖ１．７モノクローナル抗体を含む医薬組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214973B1 (en) 1993-11-19 2001-04-10 Chugai Seiyaku Kabushiki Kaisha Reshaped human antibody to human medulloblastoma cells
DE69535243T2 (de) 1994-07-13 2007-05-10 Chugai Seiyaku K.K. Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
EP0962467A4 (en) 1996-09-26 2002-10-30 Chugai Pharmaceutical Co Ltd Antibody against human parathormone related peptides
CN102781963B (zh) 2009-10-27 2018-02-16 Ucb医药有限公司 功能修饰性NAv1.7抗体
GB0922434D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
MX2015010749A (es) 2013-03-14 2015-11-30 Regeneron Pharma Anticuerpos humanos para nav1.7.
JP2016529909A (ja) * 2013-09-05 2016-09-29 デューク ユニバーシティ Ｎａｖ１．７抗体及び前記抗体を使用する方法
GB2517953A (en) 2013-09-05 2015-03-11 Argen X Bv Antibodies to complex targets
JPWO2019230856A1 (ja) * 2018-05-31 2021-06-24 塩野義製薬株式会社 Ｎａｖ１．７モノクローナル抗体
US20240002497A1 (en) 2020-11-19 2024-01-04 Merck Sharp & Dohme Llc Nav1.7 binders
WO2024225446A1 (ja) * 2023-04-28 2024-10-31 塩野義製薬株式会社 新規なＮａｖ１．７モノクローナル抗体を含む医薬組成物

Also Published As

Publication number Publication date
CA3236404A1 (en) 2023-05-04
JPWO2023074888A1 (https=) 2023-05-04
WO2023074888A1 (ja) 2023-05-04
TWI867354B (zh) 2024-12-21
EP4428239A4 (en) 2025-10-29
IL311683B2 (en) 2026-04-01
JP7457880B2 (ja) 2024-03-28
IL311683B1 (en) 2025-12-01
KR20240099394A (ko) 2024-06-28
MY206945A (en) 2025-01-21
TW202325739A (zh) 2023-07-01
AU2022377536A1 (en) 2024-04-11
EP4428239A1 (en) 2024-09-11
AU2022377536B2 (en) 2024-10-24
MX2024004393A (es) 2024-04-30
US20250163145A1 (en) 2025-05-22
IL311683A (en) 2024-05-01
CO2024003915A2 (es) 2024-04-18

Similar Documents

Publication Publication Date Title
US20230120270A1 (en) New polypeptide complex
KR20210049792A (ko) 인간 il-4r 결합 항체, 이의 항원 결합 단편, 및 이의 의학적 용도
CN113039208B (zh) 一种抗pd-l1抗原结合蛋白及其应用
BR112013010688B1 (pt) combinações de anticorpos c-met
US11643458B2 (en) Monoclonal antibody against Nav1.7
CN104011206B (zh) 新型抗人ctgf抗体
JP2020532279A (ja) 抗ｇｉｔｒ抗体、その抗原結合性断片、およびその医薬用途
KR102753603B1 (ko) 신규한 Nav1.7 모노클로날 항체
CN106062193B (zh) 与人tlr2及人tlr4结合的双特异性抗体
WO2024225446A1 (ja) 新規なＮａｖ１．７モノクローナル抗体を含む医薬組成物
CN118638234B (zh) 抗bdca2抗体及其制备方法和应用
JP2024534706A (ja) 二重特異性抗体及びその使用
HK40110725A (en) Novel nav1.7 monoclonal antibody
BR112024005503B1 (pt) Anticorpo monoclonal ou seu fragmento de anticorpo que se liga especificamente a nav1.7 humana
CN118119711A (zh) 新的Nav1.7单克隆抗体
JPWO2019054460A1 (ja) 抗ｒａｍｐ２抗体
JP7419544B2 (ja) 抗ＩＬ－１β抗体
RU2776821C2 (ru) Моноклональное антитело к nav1.7
CN119301153A (zh) 结合il-17a和il-17f的抗体分子及其应用
HK40113191A (zh) 犬白介素-31受体αI的犬源化抗体
HK40076302A (en) New polypeptide complex
CN118525034A (zh) 犬白介素-31受体αI的犬源化抗体
HK40049635A (en) Anti-pd-l1 antigen binding protein, and application thereof
HK40049635B (en) Anti-pd-l1 antigen binding protein, and application thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240530

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240530

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20240530

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240624

Patent event code: PE09021S01D

PG1501 Laying open of application
E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20241107

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250108

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250108

End annual number: 3

Start annual number: 1

PG1601 Publication of registration